Pulmonary Tuberculoses
16
1
3
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
13%
2 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (16)
Vitamin D and Immune Response in Pulmonary Tuberculosis With and Without Chronic Pulmonary Aspergillosis
Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis
Evaluation of PATHFAST-LAM as a Tuberculosis Treatment Monitoring Tool in Kenya
Pulmonary Aspergillosis in Tuberculosis Patients
Evaluating Newly Approved Drugs for Multidrug-resistant TB
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Economic Evaluation of New MDR TB Regimens
Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis
Prevalence and Burden of Bronchiectasis in Tuberculous Patients
Time-to-Detection in Culture of Mycobacterium Tuberculosis
BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
A Retrospective Cohort Study to Develop Markers for TB Severity and Treatment Progress
Lung Health After Tuberculosis: Clinical and Functional Assessment in Post Pulmonary Tuberculosis Egyptian Patients.
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial
Safety and Immunogenicity Study of GX-70 in TB Patient
Line Probe Assay Evaluation Study